Drug Trial Radar · NCT01121835
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Last checked: Nov 20, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
934
Actual
Start
Feb 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below 7% at the end of treatment and who do not experience documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) below 56 mg/dL (3.1 mmol/L)) over a 24-week treatment period, in Type 2 diabetes patients failing lifestyle management and oral agents. Secondary Objectives: To assess the effect of insulin glargine in comparison with premixed insulin on : * Evolution of HbA1c level during the treatment period Percentage of patients who reach the target of HbA1c \< 7 % and who do not experience documented symptomatic hypoglycemia confirmed by a Plasma Glucose (PG) below 70 mg/dL (3.9 mmol/L) * Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 56 mg/dL (3.1 mmol/L) \>Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 70 mg/dL (3.9 mmol/L) \>Evolution of Fasting Plasma Glucose Evolution of 7-point plasma glucose profiles * Evolution of weight * Hypoglycemia occurrence * Dose of insulins * Evolution of liver function * Overall safety
Conditions
- Diabetes Mellitus, Type 2
Interventions
INSULIN GLARGINEDrug
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
INSULIN GLULISINEDrug
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
PREMIXED INSULINDrug
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico * 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L]Time frame: From baseline (visit 2, week 0) to visit 14 (week 24)
Locations
96 sites in 16 countries. Site status is shown where the registry gives one.
Investigational Site Number 040-004
Sankt Stefan, Austria
Investigational Site Number 040-002
Vienna, Austria
Investigational Site Number 040-001
Vienna, Austria
Investigational Site Number 040-003
Vienna, Austria
Investigational Site Number 076002
Belém, Brazil
Investigational Site Number 076005
Curitiba, Brazil
Investigational Site Number 076004
Fortaleza, Brazil
Investigational Site Number 076001
Porto Alegre, Brazil
Investigational Site Number 076003
São Paulo, Brazil
Investigational Site Number 156004
Beijing, China
Investigational Site Number 156005
Beijing, China
Investigational Site Number 156006
Beijing, China
Investigational Site Number 156011
Chongqing, China
Investigational Site Number 156009
Dalian, China
Investigational Site Number 156008
Guangzhou, China
Investigational Site Number 156012
Haikou, China
Investigational Site Number 156007
Nanjing, China
Investigational Site Number 156001
Shanghai, China
Investigational Site Number 156002
Shanghai, China
Investigational Site Number 156003
Shanghai, China
Investigational Site Number 156010
Shenyang, China
Investigational Site Number 170001
Bogotá, Colombia
Investigational Site Number 170002
Bogotá, Colombia
Investigational Site Number 170003
Bucaramanga, Colombia
Investigational Site Number 170005
Manizales, Colombia
Investigational Site Number 170004
Pereira, Colombia
Investigational Site Number 208-001
Hvidovre, Denmark
Investigational Site Number 208-003
København NV, Denmark
Investigational Site Number 208-002
København S, Denmark
Investigational Site Number 300006
Alexandroupoli, Greece
Investigational Site Number 300001
Athens, Greece
Investigational Site Number 300002
Athens, Greece
Investigational Site Number 300003
Athens, Greece
Investigational Site Number 300004
Athens, Greece
Investigational Site Number 300005
Irakleio, Greece
Investigational Site Number 300011
Maroussi, Athens, Greece
Investigational Site Number 300008
Thessaloniki, Greece
Investigational Site Number 300010
Thessaloniki, Greece
Investigational Site Number 300007
Thessaloniki, Greece
Investigational Site Number 356008
Bangalore, India
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.